OverviewChartProfileKey statisticsFinancialsNewsTraderScreen

Kuros Bioscience Ltd./  CH0325814116  /

Nasdaq Other OTC
6/10/2024  6:51:27 PM Chg. +2.0100 Volume Bid- Ask- Market Capitalization Dividend Y. P/E Ratio
13.0400USD +18.22% 1,200
Turnover: 14,628		 -Bid Size: - -Ask Size: - 466.41 mill.USD - -
GlobeNewswire 2/3/2022 Kuros Biosciences’s MagnetOs Granules Cleared by FDA for Expanded Spinal Indications
GlobeNewswire 10/26/2021 Kuros Biosciences Reports Continued Increase in MagnetOs U.S. Sales
GlobeNewswire 9/28/2021 Kuros Biosciences to Showcase New MagnetOs Products at NASS 2021 Annual Meeting
GlobeNewswire 7/15/2021 Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a royal...
GlobeNewswire 3/18/2021 Kuros Biosciences Reports Results for the Full Year 2020
GlobeNewswire 3/10/2021 Kuros Biosciences to Present at Upcoming Clinical and Investor Conferences
GlobeNewswire 3/2/2021 Kuros Biosciences Announces MagnetOs Sales and Distribution Agreements Across Northern Europe
GlobeNewswire 9/9/2020 CORRECTING AND REPLACING -- Kuros Biosciences’s Licensee Checkmate Pharmaceuticals Completes its IPO...
GlobeNewswire 9/9/2020 Kuros Biosciences’s licensee Checkmate Pharmaceuticals completes its IPO on NASDAQ
GlobeNewswire 9/1/2020 Kuros Biosciences Announces Treatment of the First Patient in its Spinal Fusion Trial with Fibrin-PT...
GlobeNewswire 8/12/2020 Kuros Biosciences Reports Results for First Half 2020
GlobeNewswire 7/22/2020 Kuros Biosciences Further Strengthens Orthobiologics Patent Portfolio
GlobeNewswire 3/26/2020 Kuros Biosciences Reports Results for the Full Year 2019
GlobeNewswire 3/18/2020 Kuros Strengthens Orthobiologics Patent Portfolio
GlobeNewswire 1/30/2020 Kuros Reports Publication of MagnetOs Preclinical Data Demonstrating Superiority to Market-Leading S...
GlobeNewswire 10/2/2019 Kuros Biosciences to Host Key Opinion Leader Meeting in Zurich Showcasing its Commercial Stage Advan...
GlobeNewswire 9/24/2019 Kuros Biosciences announces full commercial launch of MagnetOs™ and exhibitor status at North Americ...
GlobeNewswire 9/3/2019 Kuros Biosciences Announces U.S. FDA approval of IND Application to Initiate Fibrin-PTH Phase 2a Cli...
GlobeNewswire 8/20/2019 Kuros Biosciences Reports Results for First Half 2019
GlobeNewswire 7/9/2019 Kuros Biosciences Signs Agreement with Surgical Specialties on Distribution of MagnetOs in Australia...
GlobeNewswire 4/30/2019 Kuros Biosciences to Propose Re-Appointment of Chairman and Board Members at Annual General Meeting
GlobeNewswire 4/12/2019 Kuros Biosciences Reports Results for the Full Year 2018
GlobeNewswire 4/9/2019 Kuros Biosciences Enters Convertible Bond Financing Agreement For Up To CHF 5 Million
GlobeNewswire 3/13/2019 Kuros Biosciences Receives US Marketing Clearance for Intervertebral Body Fusion Device
GlobeNewswire 2/11/2019 Kuros Biosciences Signs Agreement to Supply SeaSpine with Bone Graft Incorporating Kuros’s Advanced ...